TRGNF:OTO-Transgene S.A. (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 1.59

Change

0.00 (0.00)%

Market Cap

USD 0.11B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Transgene SA is a biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 36.93B
UCBJY UCB SA ADR

N/A

USD 36.22B
UCBJF UCB SA

N/A

USD 36.22B
GNMSF Genmab A/S

N/A

USD 13.91B
WXIBF WuXi Biologics

N/A

USD 10.26B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 9.12B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.24B
ZLDPF Zealand Pharma A/S

N/A

USD 8.01B
IVBIY IVBIY

N/A

USD 7.83B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.73B

ETFs Containing TRGNF

PCIG Litman Gregory Funds Trus.. 8.27 % 0.00 %

N/A

USD 0.03B
EUDV ProShares MSCI Europe Div.. 2.58 % 0.55 %

N/A

USD 6.36M
BIS ProShares UltraShort Nasd.. 2.25 % 0.95 %

N/A

USD 4.38M
MVEE:SW iShares Edge MSCI Europe .. 1.79 % 0.00 %

N/A

USD 0.05B
IESZ:SW iShares Edge MSCI Europe .. 0.54 % 0.00 %

N/A

USD 0.02B
IWSZ:SW iShares Edge MSCI World S.. 0.15 % 0.00 %

N/A

USD 0.29B
IWFS:LSE iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.29B
IWSZ:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.29B
XS8R:LSE Xtrackers MSCI Europe Inf.. 0.00 % 0.00 %

N/A

USD 0.04B
CEMT:F iShares Edge MSCIope Size.. 0.00 % 0.00 %

N/A

USD 0.02B
CEMT:XETRA iShares Edge MSCIope Size.. 0.00 % 0.00 %

N/A

USD 0.02B
EXV3:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.21B
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.85% 63% D 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.85% 63% D 52% F
Trailing 12 Months  
Capital Gain -1.85% 63% D 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.85% 63% D 52% F
Trailing 5 Years  
Capital Gain -12.15% 77% C+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.15% 75% C 52% F
Average Annual (5 Year Horizon)  
Capital Gain 2,240.80% 93% A 97% N/A
Dividend Return 2,240.80% 93% A 97% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5,664.00% 10% F 5% F
Risk Adjusted Return 39.56% 92% A 76% C+
Market Capitalization 0.11B 80% B- 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector